Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
Zacks·2d ago
More News
Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks·3d ago
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
Zacks·3d ago
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Zacks·3d ago
What to Know About This Fund's $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
Key PointsCaprock Group sold 416,686 shares of Liquidia in the first quarter; the estimated trade size was $15.46 million based on quarterly average prices...
Nasdaq News: Markets·4d ago
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Zacks·4d ago
Best Momentum Stocks to Buy for May 13th
LQDA, NEXA and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 13th, 2026.
Zacks·4d ago
New Strong Buy Stocks for May 13th
HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.
Zacks·5d ago
These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share and sales of $132.865 million. Analysts raised price targets on LQDA stock.read more...